introduction consensus process {#s0010}
==============================

See [supplementary Material, available at Annals of Oncology online (Table 7)](#ec0010){ref-type="fig"} .Supplement MaterialSupplement MaterialSupplement Material

clinical baseline {#s0015}
=================

See [supplementary Material, available at Annals of Oncology online](#ec0010){ref-type="fig"}.

diagnostic procedures {#s0020}
=====================

With respect to the critical prognosis of lung infiltrates (LI) in febrile neutropenic patients, diagnostic procedures are of major importance, but should not cause a substantial delay in the start of adequate antimicrobial therapy.

imaging {#s0025}
-------

Conventional chest radiographs show abnormalities in \<2% of febrile neutropenic patients without clinical findings indicating lower respiratory tract infection \[[@bb0015], [@bb0020], [@bb0025]\]. It is undetermined how many of these patients would have abnormalities on computed tomography (CT) scans, because no randomized head-to-head comparisons have been published so far. In patients persistently febrile after \>48 h of broad-spectrum antibacterial therapy, ∼10% of chest radiographs are abnormal, whereas high-resolution CT scans at this time reveal pathological findings in ∼50% of patients \[[@bb0030], [@bb0035]\]. Early detection of lesions indicating invasive mold infection or *Pneumocystis* pneumonia (PcP) is of utmost importance, facilitating targeted bronchoscopy and bronchoalveolar lavage (BAL) and a prompt institution of pre-emptive antimicrobial treatment \[[@bb0040], [@bb0045], [@bb0050]\], enabling better survival of these patients. CT findings such as consolidation, 'halo sign' and 'air-crescent sign', obtained by high-resolution or multislice CT scans, may be important signs of filamentous fungal disease \[[@bb0045], [@bb0055]\]. While the 'halo sign' has been described typically in neutropenic patients, other CT findings indicative of IPA are comparable in neutropenic and in non-neutropenic patients \[[@bb0060]\]. A 'reversed halo sign', showing a focal rounded area of ground-glass opacity surrounded by a crescent or complete ring of consolidation, has been reported as relatively specific for fungal pneumonia due to zygomycetes/mucorales \[[@bb0045]\]; however, it may represent a broad spectrum of other differential diagnoses including tuberculosis, sarcoidosis or cryptogenic organizing pneumonia \[[@bb0065]\].

Beyond early identification of LI, CT findings may allow for distinguishing fungal from nonfungal LI \[[@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095]\]. Diffuse bilateral perihilar infiltrates, patchy areas of ground-glass attenuation (peripheral sparing), cysts and septal thickening, consolidation and centrilobular nodules may indicate PcP \[[@bb0100], [@bb0105], [@bb0110]\]. Nodular or cavitary lesions are suggestive of invasive filamentous fungal infection; however, differential diagnoses include pneumonia due to other microorganisms including mycobacteria \[[@bb0115]\] (which may be relevant in regions with high prevalence), *Nocardia*, *Pneumocystis* or *Pseudomonas aeruginosa* (*P. aeruginosa*) as well as lung involvement by underlying malignancies \[[@bb0120]\], so that comparison to previous CT scans in an individual patient is essential. Combination of CT scan with angiography has been found to increase the diagnostic specificity in some patients with pulmonary mold infections \[[@bb0125], [@bb0130]\]; however, this more labor intensive method has not yet become widely applied and is therefore not included into current clinical practice guidelines. In selected patients where pulmonary CT scan is not wanted or feasible, magnetic resonance tomography (MRI) is a valid alternative (B-II) \[[@bb0135], [@bb0140]\]. As yet, consensus definitions of invasive fungal diseases \[[@bb0055]\] have not included thoracic MRI findings. In selected patients with unexplained fever during neutropenia, \[^18^F\]2-fluoro-2-deoxy-D-glucose--positron emission tomography combined with computed tomography (PET-CT) may be helpful, particularly to rule out undetected infection \[[@bb0145]\].

Follow-up thoracic CT scans should in general not be ordered \<7 days after start of treatment (A-II). In patients with IPA may show increasing volume of pulmonary infiltrates during the first week despite effective antifungal therapy \[[@bb0150]\]. This finding alone should not give reason to assess the treatment course as refractory (A-II). Reduction of the 'halo' and the development of an 'air-crescent' sign, however, typically indicate favorable response \[[@bb0155]\].

microbiology and histopathology {#s0030}
-------------------------------

In the majority of febrile neutropenic patients with LI, no proving microbiological finding is available, so that the therapeutic management is based upon clinical and imaging findings (see below). In microbiologically documented cases, pathogens typically are isolated from blood cultures, bronchial secretions or BAL fluid. It often means a challenge to assess the diagnostic relevance of culture results \[[@bb0160], [@bb0165], [@bb0170], [@bb0175]\], because unselected bronchial samples from these patients grow colonizing and contaminating microorganisms with no etiological significance \[[@bb0180]\], or blood cultures may show isolates not etiologically related to pneumonias. At the same time, if autopsies show invasive fungal infections, 75% of them have not been detected ante mortem \[[@bb0185], [@bb0190]\]. Therefore, in contrast to the majority of other microbiological findings, isolation of *Aspergillus* spp. or other filamentous fungi from upper respiratory tract specimens of severely immunocompromised patients typically indicates a respiratory tract mycosis \[[@bb0195]\].

The diagnostic yield and the outcome of clinical management in critically ill, febrile cancer patients with severe pulmonary infiltrates have not been improved by invasive diagnostic procedures including BAL \[[@bb0200]\]. The detection rate of potential pathogens from BAL samples has been described to be 25%--50% or even higher \[[@bb0060], [@bb0205], [@bb0210], [@bb0215]\], depending on the risk profile of patients included. A retrospective analysis of microbiological findings from BAL samples in cancer patients with LI showed 34% bacteria, 22% cytomegalovirus (CMV), 15% *Pneumocystis jirovecii* (*P. jirovecii*) and 2% *Aspergillus* spp. \[[@bb0220]\], and another report of 246 bronchoscopies in 199 febrile patients with hematological malignancies described pathogens with possible etiological significance in 48% of samples, of which 70 samples grew only bacteria, 13 showed both fungi and bacteria, 15 samples *Aspergillus* spp., 16 samples *Candida* species and 2 samples both *Aspergillus* and *Candida* spp*.* \[[@bb0170]\]. Many LI in severely immunocompromised patients may also have polymicrobial etiology \[[@bb0175]\], with molds (predominantly *Aspergillus* spp.) plus bacteria in 12% and multiple fungal species in 22% of samples. Although the etiological relevance of BAL findings may be questionable in many cases, the results trigger the change of antimicrobial treatment in up to 50% of patients \[[@bb0170], [@bb0225], [@bb0230]\]. As a diagnostic 'gold standard' is lacking, the number of false-positive and false-negative findings are unknown, and the rates of success or failure of 'pathogen-directed' antimicrobial treatment therefore remain undetermined. A proposal for the assessment of the etiological significance of microbiological findings in febrile neutropenic patients with LI is given in antimicrobial treatment in patients with documented pathogens section.

While for the proven diagnosis of IPA, cultural isolation of fungi and histological proof from lung tissue are regarded as diagnostic 'gold standard' \[[@bb0055]\], quality standards for diagnostic procedures are not available and patients undergoing biopsy are highly selected. Histological proof alone has an accuracy for *Aspergillus* of around 78%, so that histology should always be combined with fungal culture and with a culture independent method, e.g. nucleic acid based \[[@bb0235]\]. Polymerase chain reaction (PCR) may be helpful especially in patients who already receive antifungal treatment and for difficult-to-culture pathogens such as Mucorales.

Transbronchial biopsy is not recommended in severely thrombocytopenic patients with lung infiltrates \[[@bb0230]\]. Open-lung biopsy (OLB), mini-thoracotomy or video-assisted thoracoscopic surgery may be safely carried out in patients with treatment-refractory LI not cleared-up by other diagnostic approaches, primarily in order to rule out noninfectious origin \[[@bb0215], [@bb0240], [@bb0245], [@bb0250], [@bb0255]\]. OLB is a relatively safe procedure with a complication rate of ∼6% \[[@bb0260]\], including the risk of hemorrhage \[[@bb0250], [@bb0265]\] even in thrombocytopenic patients \[[@bb0260], [@bb0270]\]. Histologically, no infection or malignancy, but nonspecific inflammation is detected in the majority of patients \[[@bb0160], [@bb0260], [@bb0270]\]. Notably, findings from OLB and BAL obtained simultaneously may show different microbiological results \[[@bb0160]\].

CT-guided percutaneous side-cut core needle biopsy may provide informative results in ∼80% of cases, allowing for species identification using molecular methods for tissue workup \[[@bb0275], [@bb0280], [@bb0285], [@bb0290], [@bb0295]\]. Percutaneous biopsy requires platelet counts \>50 000/µl plus sufficient coagulation indices, e.g. an aPTT ratio of ≤1.4 \[[@bb0300]\], and should be limited to patients without an obvious risk of respiratory failure in case of complications such as a pneumothorax. As yet, there are no reports from prospective studies comparing different methods for invasive approaches to identify the causes of LI in febrile neutropenic patients.

nonculture-based diagnostic methods {#s0035}
-----------------------------------

### cytomegalovirus and respiratory viruses {#s0040}

In patients with profound cellular immunosuppression, respiratory viruses may be the cause of LI, so that diagnostic programs used for workup of BAL or oro-/nasopharyngeal swabs should include CMV as well as *Influenza*, *Parainfluenza*, *Respiratory Syncytial Virus*, Coronavirus, Rhinovirus and *Human Metapneumovirus* \[[@bb0305], [@bb0310], [@bb0315], [@bb0320]\]. In febrile neutropenic patients with LI, CMV PCR applied on BAL samples has a high negative, but low positive predictive value \[[@bb0325]\], while positive rapid culture, immediate early antigen, direct fluorescent antibody tests, DNA hybridization or cytology from BAL cultures are required to confirm the diagnosis of CMV pneumonia \[[@bb0330], [@bb0335]\].

### Pneumocystis jirovecii {#s0045}

Besides microscopic identification, which has been the classical reference method for detecting *P. jirovecii*, PCR has been introduced in the 1990s for early detection of this pathogen with a high sensitivity \[[@bb0340]\]. It is essential to distinguish between infection and colonization, which may be present in \>50% of individuals without signs or symptoms of PcP \[[@bb0345]\]. A meta-analysis showed a very high sensitivity of 99% and a specificity of 90% \[[@bb0350]\], so that a negative *Pneumocystis*-PCR from a BAL sample at the time of diagnosis allows to put aside anti-*Pneumocystis* therapy \[[@bb0355]\]. More recently developed quantitative PCR assays appear to increase the specificity \[[@bb0360], [@bb0365]\]. A report on 71 non-HIV patients with proven PcP showed a positive predictive value of 98% when \>1450 pathogens per ml were detected in BAL samples \[[@bb0370]\]. Determining β-[d]{.smallcaps}-glucan in serum may add to the differential diagnosis \[[@bb0375], [@bb0380]\], because a negative result of this test makes PcP highly unlikely \[[@bb0385]\].

### filamentous fungi {#s0050}

Numerous methods have been developed for detecting fungal cell antigens such as *Aspergillus* galactomannan (GM), 1,3-β-[d]{.smallcaps}-glucan or nuclear amplification assays to identify fungal DNA for early noninvasive detection of filamentous fungi in febrile neutropenic patients with LI of undetermined etiology \[[@bb0390], [@bb0395], [@bb0400], [@bb0405], [@bb0410]\]. A positive (i.e. \>0.5 OD) GM test from blood or from BAL samples, where a cutoff of ≥1.0 might be more appropriate \[[@bb0415]\], has been accepted as a significant finding indicating a probable invasive fungal infection in severely immunocompromised patients \[[@bb0420], [@bb0425]\]. It is questionable if *Aspergillus* GM in blood will become positive earlier than a chest CT scan \[[@bb0430]\]. Notably, the GM test may give false-positive results in patients treated with semisynthetic β-lactam antibiotics such as amoxicillin--clavulanate, piperacillin--tazobactam, carbapenems, ceftriaxone or cefepime \[[@bb0435], [@bb0440]\] as well as in those given enteral nutrition \[[@bb0445]\], those with other fungal infections such as fusariosis \[[@bb0450]\] and in BAL samples obtained using specific lavage solutions such as Plasmalyte™ \[[@bb0455]\]. False-positive *Aspergillus* antigenemia may also be due to blood product conditioning fluids \[[@bb0460]\]. A significant decline in the galactomannan *Aspergillus* antigen signal was described during storage of serum samples, in contrast to BAL samples, so that the time from taking a blood sample to testing should be minimized \[[@bb0465]\].

Details on antigen testing for fungal infection, including those other than aspergillosis \[[@bb0470]\], have been reviewed in a separate evidence-based guideline of our group \[[@bb0475]\].

Studies on panfungal or *Aspergillus*-specific PCR assays indicate that the use of these techniques on BAL samples seems superior when compared with blood samples, particularly in patients undergoing systemic antifungal therapy \[[@bb0410], [@bb0425], [@bb0480], [@bb0485], [@bb0490]\]. On lung biopsy specimens, PCR added to histopathology and culture may improve specification of pathogens \[[@bb0295]\]. Since there is no widely accepted international standardization of these assays available as yet for blood and BAL samples \[[@bb0495]\], PCR results have not become part of definition criteria for invasive fungal infections by now \[[@bb0055], [@bb0475], [@bb0500]\]. PCR presumably will become part of a diagnostic program for LI, including thoracic CT scans, serology and conventional microbiology from blood and BAL samples \[[@bb0505]\]. The combination of *Aspergillus* PCR and GM in BAL samples enhances diagnostics since positive results for both GM and PCR make a pulmonary aspergillosis highly likely \[[@bb0505]\], as confirmed recently by meta-analyses \[[@bb0510], [@bb0515]\].

Previous exposure to antifungal therapy may reduce the sensitivity of the galactomannan as well as quantitative PCR assays \[[@bb0520], [@bb0525]\].

### *Legionella pneumophila* serogroup 1 antigen {#s0055}

While nosocomial outbreaks of legionellosis among cancer and leukemia patients have become very rare, a single-center report from 2007 has indicated that this differential diagnosis should not be ignored \[[@bb0530]\]. Testing of *Legionella pneumophila* serogroup 1 in urine helps to detect this diagnosis rapidly. Controlled clinical studies on the usefulness of routine testing for this antigen among febrile neutropenic patients with lung infiltrates are not available.

### biomarkers {#s0060}

Nonspecific proinflammatory laboratory parameters like C-reactive protein, interleukin-6 \[[@bb0535]\], interleukin-8, tumor necrosis factor-α or procalcitonin plasma levels \[[@bb0540]\] are frequently used to assess the severity of infections and the response to antimicrobial therapy. In febrile neutropenic patients with LI, the predictive value of these parameters has not been investigated in prospective studies as yet. In clinical practice, the repeated measurement of these parameters typically parallels clinical observation and should be used for therapeutic decisions only in the context with clinical and imaging findings. Persisting fever, progressive or newly emerged LI and rising proinflammatory parameters typically indicate the need for a change in the antimicrobial treatment regimen \[[@bb0545]\].

algorithms for the clinical management of febrile neutropenic patients with LI {#s0065}
==============================================================================

An algorithm for the clinical management of febrile neutropenic patients with LI is proposed in [Figure 1](#f0010){ref-type="fig"} . Synopses of recommendations for diagnostic measures are given in [Table 1](#t0010){ref-type="table"}, [Table 2](#t0015){ref-type="table"}, [Table 3](#t0020){ref-type="table"}, [Table 4](#t0025){ref-type="table"} . Recommendations for antimicrobial treatment and clinical management are summarized in [Tables 5](#t0030){ref-type="table"} and [6](#t0035){ref-type="table"} .Figure 1Diagnostic procedures and treatment of neutropenic patients with fever and suspected or proven lung infiltrates.Figure 1Table 1Recommendations for imaging diagnostic proceduresTable 1RecommendationStrengthIn febrile neutropenic patients with signs or symptoms of lower respiratory tract infection, multislice or high-resolution computed tomography (CT) scan of the lungs is the diagnostic method of choiceA-IIConventional chest radiographs are not recommended for the diagnosis of lung infiltrates in febrile neutropenic patientsE-IIIf a pulmonary CT scan is not feasible, MRI of the lungs is recommendedB-IIIn most cases, thoracic CT scan can be done without contrast mediaB-IIMultislice or high-resolution CT scan must be available at a maximum of 24 h after clinical indication has been establishedA-IIIf infiltrates are detected on pulmonary CT scans, bronchoalveolar lavage should be carried out at a segmental bronchus supplying an area of radiographic abnormalitiesB-IIIWhenever possible, thoracic CT showing abnormalities scans should be compared with previous scansA-IICT or magnetic resonance angiography may be considered if feeding vessel sign, reversed halo sign or hemoptysis are observed in suspected fungal pneumoniaB-IIITable 2Recommendations for bronchoscopy and bronchoalveolar lavage (BAL)Table 2RecommendationStrengthBronchoscopy and bronchoalveolar lavage should be carried out using a standardized protocolA-IITransbronchial biopsies are not recommended in febrile neutropenic (and thrombocytopenic) patientsD-IIIf a tissue sample for histological, microbiological and molecular workup is required, CT-guided side-cut percutaneous biopsy, video-assisted thoracoscopy or open-lung biopsy should be usedB-IIMicrobiological workup of BAL samples should follow a standardized protocol.B-IIBronchoscopy and BAL should be available within 24 h after clinical indication has been establishedB-IIIUrgent need to start or modify antimicrobial therapy should not be postponed by bronchoscopy and BALA-IIBronchoscopy and BAL should only be carried out in patients without critical hypoxemiaB-IITable 3Diagnostic workup of bronchoalveolar lavage (BAL) samples from febrile neutropenic patients with lung infiltratesTable 3Recommended diagnostic programEvidence levelCytospin preparations for distinguishing intracellular from extracellular pathogens and identifying infiltration by underlying malignancyBGram stainBGiemsa or May-Grünwald-Giemsa stain (assessment of macrophages, ciliated epithelium, leukocytes)B*Mycobacterium tuberculosis* (*M. tuberculosis*) polymerase chain reaction (PCR)APCR for *Pneumocystis jirovecii* (*P. jirovecii*); quantitative if possibleACalcofluor white or equivalent (assessment of fungi and *P. jirovecii*)ADirect immunofluorescence test for *P. jirovecii* (confirmatory)A*Aspergillus* antigen (Galactomannan Sandwich ELISA)ABacteriological cultures (Quantitative or semi-quantitative): dilutions of 10^-2^ and 10^-4^; culture media: blood agar, MacConkey/Endo, Levinthal/blood (bacterial culture), *Legionella*-BCYE or equivalent (*Legionella* spp.), for mycobacteria at least one solid and one liquid medium (e.g. Löwenstein--Jensen agar and Middlebrook 7H9 broth or equivalent), Sabouraud/Kimmig or equivalent (fungal culture)AOptional programEnrichment culture (Brain--Heart Infusion broth, dextrose broth)C*Legionella* PCRBPCR for cytomegalovirus (CMV), *Respiratory Syncytial Virus*, influenza A/B, parainfluenza 1-3, metapneumovirus and adenovirusBQuantitative PCR for Varicella Zoster VirusBPanfungal or *Aspergillus* PCRBPeripheral blood cultures 1 h after bronchoscopy to detect transient bacteremiaCThroat swab to assess oral flora in comparison with BALCTable 4Clinical assessment of microbiological findings in febrile neutropenic patients with lung infiltratesTable 4The following findings 'indicate' pathogens causative for lung infiltrates•*P. jirovecii*, Gram-negative aerobic pathogens, pneumococci, *Nocardia*, *M. tuberculosis* or *Aspergillus* spp. or *Aspergillus* galactomannan or Mucorales obtained from bronchoalveolar lavage or sputum samples; positive rapid culture for CMV, detection of CMV 'immediate early antigen'•Isolation of pneumococci, alpha-hemolytic streptococci, *Bacillus cereus* or Gram-negative aerobic pathogens from blood culture•Any detection of pathogens with invasive growth in biopsy material•Positive *Legionella pneumophila* serogroup 1 antigen in urine•Positive *Aspergillus* galactomannan in blood (threshold 0.5) or BAL samples (cutoff of ≥1.0 might be more appropriate)•Positive quantitative *P. jirovecii* PCR with \>1450 copies/ml•Conversely, negative β-[d]{.smallcaps}-glucan in blood samples makes *Pneumocystis* pneumonia highly unlikelyThe following findings 'do not' represent pathogens causative for lung infiltrates:•Isolation of enterococci from blood culture, swabs, sputum or BAL•Coagulase-negative staphylococci or *Corynebacterium* spp. obtained from any sample•Isolation of *Candida* spp. from swabs, saliva, sputum or tracheal aspirates•Findings from surveillance cultures, feces and urine cultures.'Potentially relevant' findings include: common respiratory viruses, isolation of *Staphylococcus aureus*, *Legionella* spp. or atypical mycobacteria in respiratory secretions, positive CMV- or nonquantitative *Pneumocystis*-PCR (without confirmation by other methods) from BAL.Table 5Recommendations for antimicrobial treatment and clinical management---ITable 5RecommendationStrengthFebrile neutropenic patients with LI not typical for *Pneumocystis* pneumonia (PcP) or lobar bacterial pneumonia should receive mold-active systemic antifungal therapyA-IIPreferred first-line therapy in this setting is voriconazole or liposomal amphotericin BA-II-Patients under current oral posa- or voriconazole prophylaxis should be switched to liposomal amphotericin BC-IIIThe dosage of antifungal drugs in this setting is equal to the dosage used for proven mold infectionB-IIIIn severely neutropenic, hospitalized patients addressed here, antiviral agents, macrolide antibiotics, aminoglycosides or fluoroquinolones should only be given based on a conclusive microbiological findingD-IIIf PcP is suspected because of the pattern of lung infiltrates and new LDH elevation, treatment should be initiated also before bronchoscopy and BALB-IIPositive quantitative PCR (\>1450 copies/ml) for *P. jirovecii* from BAL should trigger the start of systemic *Pneumocystis* treatmentB-IIFirst choice for treatment of PcP is high-dose trimethoprim--sulfamethoxazole (TMP/SMX)A-IIIn PcP patients intolerant of or refractory to high-dose TMP/SMX, a combination of clindamycin plus primaquine is the preferred alternativeB-IIIn (non-HIV) patients with critical respiratory insufficiency due to PcP, adjunctive administration of glucocorticosteroids is not generally recommended and should only be considered in individual patientsC-IIPatients who have been successfully treated for PcP should receive secondary oral prophylaxis to prevent PcP recurrenceA-IIDrugs of choice for secondary PcP prophylaxis are intermittent TMP/SMX or monthly aerosolized pentamidineB-IITable 6Recommendations for antimicrobial treatment and clinical management---IITable 6RecommendationStrengthIn patients with documented *P. aeruginosa* pneumonia, treatment with an antipseudomonal β-lactam plus an aminoglycoside is preferred when local *in vitro* resistance patterns indicate suboptimal activity of antipseudomonal β-lactam antibioticsB-IIAntipseudomonal β-lactams suitable for treatment of *P. aeruginosa* pneumonia are piperacillin (±tazobactam), ceftazidime, imipenem/cilstatin, meropenem or cefepimeA-IIn patients who cannot be treated with an aminoglycoside, the antipseudomonal β-lactam should be combined with ciprofloxacinB-IIThe preferred regimen for documented *S. maltophilia* pneumonia is TMP/SMXA-IIThe dose of TMP/SMX for treatment of *S. maltophilia* pneumonia is similar to the treatment of *P. jirovecii* pneumoniaB-IIIPreferred treatment regimens for CMV pneumonia are i.v. ganciclovir or foscarnetA-IIThe selection between ganciclovir and foscarnet should be based on the known toxicity profiles of these compounds and, if present, known resistance patternsA-IIResponse to antimicrobial treatment should be clinically assessed on a daily basisA-IIImaging studies to re-assess treatment response should generally not be ordered earlier than after 7 days of antimicrobial treatmentB-IIIn patients with lack of clinical improvement, CT scan should be repeated after 7 days of treatmentB-IIPersisting fever, progressive or newly emerged LI and rising proinflammatory parameters after 7 days of treatment typically indicate the need for repeated microbiological diagnostics and a change in the antimicrobial treatment regimenA-IIIIntensive care should unrestrictedly be provided to patients with respiratory failure unless their prognosis is desperate due to other reasonsA-IIMultidisciplinary professionals should be involved in intensive care of cancer patients with respiratory failure caused by lung infiltratesA-II

diagnostic procedures {#s0070}
---------------------

In patients with acute myeloid leukemia or myelodysplastic syndrome undergoing aggressive myelosuppressive chemotherapy expecting severe neutropenia lasting ≥10 days, serial monitoring of *Aspergillus* galactomannan from blood samples is recommended (B-II). The place for 1,3-β-[d]{.smallcaps}-glucan is not yet clearly defined, and PCR should be studied in the frame of clinical trials only. Serial panfungal PCR monitoring in patients with acute leukemia undergoing intensive myelosuppressive chemotherapy has failed to identify patients with a particularly high risk of developing invasive fungal disease \[[@bb0550]\]. Importantly, diagnostic procedures aim at obtaining microbiological results that confirm or help to modify the antimicrobial therapy, which should be initiated without awaiting results from diagnostic procedures (A-II).

Patients with fever of unknown origin not responding to an appropriate first-line therapy after 72--96 h should undergo thorough physical re-examination, imaging ([Table 1](#t0010){ref-type="table"}) and microbiological diagnostics including a native thoracic CT scan and a CT scan of paranasal sinuses if symptoms or signs of sinusitis are present (A-II). A high-resolution or multislice thoracic CT scan must be available at a maximum of 24 h after clinical indication has been established (A-II). When LI are documented, noninvasive diagnostic tests should be repeated and bronchoscopy and BAL ([Table 2](#t0015){ref-type="table"}) should be arranged within a maximum of 24 h (B-III). BAL samples must be sent immediately to the microbiological laboratory for workup, to be started within 4 h after sampling (A-III). Recommended microbiological procedures are listed in [Table 3](#t0020){ref-type="table"}. A standardized procedure for bronchoscopy and BAL is recommended (A-II) \[[@bb0560]\].

Invasive procedures such as open-lung or percutaneous core needle biopsy should be considered in patients with undetermined LI who urgently require histological identification while bronchoscopy and BAL have failed (B-II).

antimicrobial therapy in patients without documented causative pathogens {#s0075}
------------------------------------------------------------------------

Considering the dismal prognosis of febrile neutropenic patients with LI not treated promptly with an appropriate antimicrobial regimen, it is recommended to start therapy on the basis of clinical, imaging and/or laboratory findings indicative of a particular infection in patients at risk for, but without proof of this infection. The type of underlying malignancy or immunosuppression has an instrumental impact on the selection of antimicrobial agents suitable for systemic therapy. In patients without a conclusive microbiological finding ([Table 4](#t0025){ref-type="table"}) and a lack of response to antimicrobial treatment, re-assessment including thoracic CT scan and eventually also bronchoscopy and BAL should be arranged after 7 days (A-II).

### patients with severe neutropenia due to chemotherapy for acute leukemia or other aggressive hematologic malignancy {#s0080}

This subgroup of febrile neutropenic patients with LI should be treated with a broad-spectrum β-lactam with antipseudomonal activity, as used for empirical treatment of fever of unknown origin (A-II). Streptococci including cephalosporin-resistant strains \[[@bb0565]\] must be included in the antimicrobial spectrum (B-II). Additionally, patients with LI not typical for PcP or lobar bacterial pneumonia should receive mold-active systemic antifungal therapy with voriconazole or liposomal amphotericin B (A-II) \[[@bb0570]\]. This high-risk subgroup of patients has a significant benefit from prompt when compared with delayed mold-active antifungal therapy \[[@bb0575]\]. It has been shown that patients with invasive aspergillosis treated with voriconazole or liposomal amphotericin B had superior response and survival rates when treated early versus later in the course of the disease (A-II) \[[@bb0580], [@bb0585]\]. In patients pretreated with voriconazole or posaconazole for systemic antifungal prophylaxis and in whom a breakthrough filamentous fungal pneumonia is suspected, measurement of antifungal drug levels and invasive diagnostic procedures should be taken into consideration (B-III) and treatment should be switched to liposomal amphotericin B (C-III). Particularly in patients in whom mucormycosis (zygomycosis) is suspected, liposomal amphotericin B is recommended (A-II). Independent from unequivocal documentation of pulmonary fungal infection, systemic antifungal treatment should be continued until hematopoietic recovery and regression of clinical and radiological signs of infection (B-III).

In patients without a microbiologically proven indication, the addition of an aminoglycoside or 5-flucytosine is not recommended due to a lack of benefit (E-I) \[[@bb0590]\]. In patients who had not received routine anti-*Pneumocystis* prophylaxis, have a thoracic CT scan suggesting PcP, and who have a rapid and otherwise unexplained rise of serum lactate dehydrogenase, prompt start of high-dose trimethoprim--sulfamethoxazole (TMP/SMX) therapy should be considered before bronchoscopy and BAL (B-II) \[[@bb0595]\]. In case of PcP, BAL will remain positive for this pathogen over several days despite appropriate antimicrobial therapy \[[@bb0600]\].

Except from selected patients who also have a severe cellular immunosuppression, antiviral agents such as ganciclovir are not recommended for early pre-emptive therapy in febrile neutropenic patients with LI (E-II). In general, glycopeptides, fluoroquinolones or macrolide antibiotics without a specific pathogen documented from clinically significant samples should not be used as well (D-III).

### other subgroups of febrile patients with hematological malignancies {#s0085}

In individual patients undergoing high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (AHSCT) with febrile neutropenia and LI of unknown origin, whose conditioning regimen included total body irradiation or who have been treated with alemtuzumab, antithymocyte globulin or fludarabine, bronchoscopy with BAL to check for CMV disease may be considered (B-III) \[[@bb0605]\]. A positive rapid culture or 'immediate early antigen' should prompt ganciclovir treatment (5 mg/kg every 12 h) (B-III), while foscarnet has not been investigated in this setting. Since patients after AHSCT have a very low risk of fungal pneumonia \[[@bb0610], [@bb0615], [@bb0620]\], pre-emptive antifungal therapy should not be given (D-II).

antimicrobial treatment in patients with documented pathogens {#s0090}
-------------------------------------------------------------

The interpretation of microbiological findings in neutropenic patients with LI is difficult ([Table 4](#t0025){ref-type="table"}). Isolates typically originate from blood cultures or BAL samples. They may represent nonpathogenic contaminants, colonizers, co-pathogens or microorganisms causing a separate infection. If etiologically significant pathogens are detected, particularly multidrug-resistant bacteria, critical reappraisal of antimicrobial treatment to avoid fatal outcome due to delayed effective therapy is recommended (A-II) \[[@bb0625]\].

### antimicrobial treatment of complicated bacterial pneumonias {#s0095}

In patients with a documented *P. aeruginosa* pneumonia, primary combination antibacterial therapy including an antipseudomonal β-lactam plus preferably an aminoglycoside or (if an aminoglycoside is contraindicated) ciprofloxacin is recommended by many authors \[[@bb0630], [@bb0635], [@bb0640], [@bb0645]\]. However, meta-analyses have not unequivocally supported this recommendation \[[@bb0650], [@bb0655], [@bb0660]\], so that adequate β-lactam monotherapy may also be appropriate in this setting (B-II). Antipseudomonal β-lactams suitable for treatment of *P. aeruginosa* pneumonia are piperacillin (±tazobactam), ceftazidime, imipenem/cilastatin, meropenem and cefepime (A-I). Depending on their *in vitro* susceptibility pattern, multi-resistant Gram-negative aerobes such as extended-spectrum-β-lactamase-(ESBL-) producing *E. coli*, *Enterobacter* spp. or *Klebsiella* spp. as well as *Acinetobacter* spp. or *P. aeruginosa* require antimicrobial treatment selected appropriately according to this pattern (A-II). Pharmacokinetic aspects (penetration to lung tissue, possible inactivation by surfactant) must always be included in this selection (A-II). In individual patients with pneumonia caused by multi-resistant Gram-negative pathogens, aerosolized colistin has been successfully used as a part of the antimicrobial strategy \[[@bb0665]\]. *Stenotrophomonas maltophilia* (*S. maltophilia*) rarely causes pneumonia, while it is more frequently isolated from respiratory secretions representing selection of opportunistic microorganisms under broad-spectrum antibacterial treatment. In patients with suspected or documented *S. maltophilia* pneumonia, early antimicrobial intervention with high-dose TMP/SMX (15--20 mg/kg/day of trimethoprim) is recommended (B-II) \[[@bb0670], [@bb0675]\]. In individual patients, tigecycline-based treatment may be an appropriate alternative (C-II) \[[@bb0680]\]. It should be kept in mind that *in vitro* susceptibility may not predict clinical efficacy of antimicrobial agents in *S. maltophilia* infections \[[@bb0685]\].

While pneumonia caused by methicillin-susceptible *Staphylococcus aureus* (*S. aureus*) should be treated with oxacillin or flucloxacillin, methicillin-resistant *S. aureus* should preferably be treated with vancomycin, if no serious renal insufficiency is present (B-II). Linezolid is a possible alternative for first-line treatment (B-II) \[[@bb0690], [@bb0695], [@bb0700]\]; however, the risk of severe thrombocytopenia or even pancytopenia associated with linezolid must be taken into consideration \[[@bb0705]\]. Daptomycin should not be used for treatment of pneumonia, because it is inactivated by surfactant (E-I) \[[@bb0710]\].

### treatment of CMV pneumonia {#s0100}

CMV pneumonia typically affects allogeneic stem-cell transplant recipients, but is also relevant in patients treated with lymphocyte-depleting agents like alemtuzumab or fludarabine. First-choice antiviral treatment options are foscarnet or ganciclovir (A-II). Foscarnet is associated with less myelosuppression, which is a serious adverse effect of ganciclovir \[[@bb0715]\]. On the other hand, reversible nephrotoxicity is one of the typical side-effects of foscarnet \[[@bb0720]\].

### treatment of documented fungal pneumonia {#s0105}

Detailed recommendations for treatment of documented fungal pneumonia are provided in evidence-based guidelines \[[@bb0570], [@bb0725], [@bb0730]\]. Intravenous voriconazole (6 mg/kg every 12 h day 1, 4 mg/kg every 12 h thereafter) (A-I) or liposomal amphotericin B (3 mg/kg/day) (A-II) are recommended first-line choices for treatment of IPA. For mucormycosis (zygomycosis), liposomal amphotericin B is preferred (A-II), the recommended dose is ≥5 mg/kg/day (A-II). In patients with worsening LI and gas exchange within the first week of treatment, failure of antifungal therapy should only be considered if new LI emerge on control CT scans (B-III). At the same time, other causes such as a second infection, immune reconstitution syndrome, infiltrates caused by the underlying malignancy, toxicity from cancer treatment or yet insufficient duration of antifungal treatment should be ruled out (B-III) \[[@bb0735], [@bb0740]\]. Combination antifungal first-line treatment in patients with invasive mold infections is controversial. A prospective clinical study comparing voriconazole alone with the combination of voriconazole with anidulafungin in patients with proven and probable aspergillosis has not yet been published in detail \[[@bb0745]\]. For treatment of mucormycosis, a combination of liposomal amphotericin B and an echinocandin may be promising \[[@bb0750], [@bb0755]\]; however, randomized studies on this subject have not been conducted. A combination of liposomal amphotericin B and the iron chelator deferasirox for the treatment of mucormycoses has shown inferior clinical results for the combination when compared with the antifungal agent alone \[[@bb0760]\].

### treatment of documented *Pneumocystis* pneumonia {#s0110}

If PcP is suspected, treatment with TMP/SMX (co-trimoxazole) at a dosage of TMP 15--20 mg/kg plus SMX 75--100 mg/kg daily (A-II) should be initiated immediately after asservation of representative samples (e.g. induced sputum or BAL) (B-II), since treatment delay may enhance mortality \[[@bb0765], [@bb0770]\]. In mild-to-moderate cases (oxygen partial pressure pO~2~ ≥70 mmHg or alveolar-arterial oxygen difference AaDO~2~ \<45 mmHg) an oral therapy can be discussed, otherwise it should be administered i.v. In patients with proven PcP, treatment with TMP/SMX should be continued for at least 2 weeks (A-II). Clinical improvement should develop within 8 days, otherwise a second infection should be considered and diagnostic procedures repeated. In individual patients with persistent PcP, mutations in the genes for dihydropteroate synthase or dihydrofolate reductase may be taken into consideration \[[@bb0775], [@bb0780], [@bb0785], [@bb0790]\]. In case of treatment failure or TMP/SMX intolerance, atovaquone oral suspension (750 mg twice times daily with meal), i.v. pentamidine (4 mg/kg daily) or clindamycin (600 mg four times daily or 900 mg three times daily i.v.) *plus* primaquine (30 mg daily p.o.) may represent treatment alternatives \[[@bb0795]\], with clindamycin + primaquine presumably being the most effective option (C-III) \[[@bb0800]\]. Glucose-6-phosphate dehydrogenase deficiency must be excluded before administration of dapsone or primaquine (A-I). Subsequently, patients should be given secondary prophylaxis (A-II) using oral TMP/SMX at a daily dosage of 160/800 mg given on 3 days per week (B-II) or with monthly pentamidine inhalation at a dose of 300 mg (B-II) \[[@bb0805], [@bb0810]\]. In patients with respiratory failure due to PcP, systemic corticosteroids may be beneficial in AIDS patients, but data are conflicting in non-HIV patients \[[@bb0815], [@bb0820]\]. Recent studies could not show a clinical benefit \[[@bb0825]\] and were even associated with increased mortality \[[@bb0830]\].

intensive care medicine {#s0115}
=======================

Reports on the outcome of cancer patients requiring intensive care have shown hospital survival rates of 60%--70% and higher \[[@bb0835], [@bb0840], [@bb0845]\]. Neutropenic patients with respiratory failure due to LI may have a favorable outcome under appropriate intensive care including mechanical ventilation \[[@bb0850], [@bb0855], [@bb0860]\]. Even if respiratory failure is due to IPA, survival can be achieved in around one third of patients \[[@bb0865]\]. It is therefore not justified to reject cancer patients from intensive care only because of their underlying malignancy \[[@bb0870]\]. Multidisciplinary care involving hematology-oncology professionals should be provided during intensive care treatment of these patients (A-II). Intensive care should unrestrictedly be provided to patients with respiratory failure (A-II), except from those whose prognosis is desperate due to other reasons or who have given a personal directive in order to abstain from it.
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This manuscript does not refer to patients undergoing allogeneic hematopoietic stem cell transplantation. These patients are subject to a separate AGIHO guideline \[[@bb0010]\].
